How Can Tumor Vasculature be Targeted in Cancer Therapy?
Targeting tumor vasculature has become a significant strategy in cancer therapy. Angiogenesis inhibitors, such as [bevacizumab](), have been developed to block the action of pro-angiogenic factors like VEGF. These inhibitors aim to normalize the tumor vasculature, reduce vessel permeability, and improve the delivery of chemotherapy agents. Another approach involves using vascular disrupting agents ([VDAs]()) that selectively target and destroy existing tumor blood vessels, leading to tumor necrosis.
